Literature DB >> 3941274

Distinguishing complicated from uncomplicated bacteremia caused by Staphylococcus aureus: the value of "new" and "old" serological tests.

H A Verbrugh, R Peters, W H Goessens, M F Michel.   

Abstract

Antibody responses to staphylococcal alpha-toxin, cell wall teichoic acid, and cell wall peptidoglycan were measured in 259 serum samples from 74 consecutive patients with Staphylococcus aureus bacteremia. All patients with complicated bacteremia were seropositive in at least one of three tests, and 18 (72%) of 25 were positive in two or three assays; six (75%) of eight patients with endocarditis were positive for all three tests. In contrast, 15 (75%) of 20 patients with uncomplicated bacteremia were positive in only one or none of the tests. These differences in antibody response patterns were statistically significant (chi 2 = 18.33, P less than .001). Patients with complicated bacteremia had peak antibody titers that were significantly higher than those of patients with uncomplicated bacteremia. The assay for antibody to alpha-toxin was as sensitive as the assays for antibody to cell wall antigens but had less specificity for complicated bacteremia. The clinical severity of the bacteremia did not correlate with a complicated vs. uncomplicated nature of the infection but was predictive of early death due to staphylococcemia. The calculated predictive values suggest that the serology of S. aureus bacteremia may be clinically valuable when multiple tests are performed in paired serum samples.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3941274     DOI: 10.1093/infdis/153.1.109

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

1.  An evaluation of the usefulness of Staphylococcus aureus serodiagnosis in clinical practice.

Authors:  J Elston; M Ling; B Jeffs; K Adams; H Thaker; P Moss; R Meigh; G Barlow
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-03-19       Impact factor: 3.267

2.  Antibody response to teichoic acid and peptidoglycan in Staphylococcus aureus osteomyelitis.

Authors:  E Jacob; L C Durham; M C Falk; T J Williams; L J Wheat
Journal:  J Clin Microbiol       Date:  1987-01       Impact factor: 5.948

3.  Antibody responses in patients with invasive Staphylococcus aureus infections.

Authors:  G Jacobsson; P Colque-Navarro; E Gustafsson; R Andersson; R Möllby
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-04-10       Impact factor: 3.267

4.  Prospective study of serum staphylococcal antibodies in cystic fibrosis.

Authors:  A E Hollsing; M Granström; B Strandvik
Journal:  Arch Dis Child       Date:  1987-09       Impact factor: 3.791

5.  Antibodies to staphylococcal peptidoglycan and its peptide epitopes, teichoic acid, and lipoteichoic acid in sera from blood donors and patients with staphylococcal infections.

Authors:  H I Wergeland; L R Haaheim; O B Natås; F Wesenberg; P Oeding
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

6.  Detection of Staphylococcus aureus by polymerase chain reaction amplification of the nuc gene.

Authors:  O G Brakstad; K Aasbakk; J A Maeland
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

7.  Antistaphylococcal antibodies in cystic fibrosis.

Authors:  B Strandvik; A Hollsing; R Möllby; M Granström
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

Review 8.  Clinical implications of positive blood cultures.

Authors:  C S Bryan
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

9.  Staphylococcus aureus bacteremia in a Dutch teaching hospital.

Authors:  M F Michel; C C Priem; H A Verbrugh; W H Goessens
Journal:  Infection       Date:  1985 Nov-Dec       Impact factor: 3.553

10.  Prospective study of serum antibodies to Pseudomonas aeruginosa exoproteins in cystic fibrosis.

Authors:  A E Hollsing; M Granström; M L Vasil; B Wretlind; B Strandvik
Journal:  J Clin Microbiol       Date:  1987-10       Impact factor: 11.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.